<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450710</url>
  </required_header>
  <id_info>
    <org_study_id>AS06005</org_study_id>
    <nct_id>NCT00450710</nct_id>
  </id_info>
  <brief_title>Neuroendocrine Brake for Type 2 Diabetes Mellitus</brief_title>
  <official_title>Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <brief_summary>
    <textblock>
      Evaluation to determine the safety of two laparoscopic procedures to control T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate neurohormonal effect in treating T2DM.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or control of blood glucose levels.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or control of comorbidities associated with T2DM.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal effect and effect of the operations on diabetes related and total mortality.</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ileal interposition with a sleeve gastrectomy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Male and female between 18 and 65 years.

          2. BMI 25.1 - 34.9.

          3. Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a
             minimum of 12 months prior the enrollment.

          4. Diagnosis of T2DM for at least 3 years.

          5. Patient has been under routine care of hte study physician or another physician that
             can supply a reliable medical record for at least 3 years.

          6. HbA1c &gt;/ 7.5 documented for at least 3 months.

          7. Stable weight (nor significant weight change (&gt;3%) over the 3 months prior to
             enrollment.

          8. Stable medication for at least one month prior to enrollment except for diabetes
             medications which should be stable for at least 3 months prior to enrollment.

          9. Ability and willingness to return for all scheduled visits and participate in
             recommended parameter setting and physician recommended medical/laboratory
             assessments.

        Exclusion Criteria:

          1. Prior abdominal surgery, except laparoscopic cholecystectomy.

          2. Taking appetite suppressant.

          3. Severe eating disorders.

          4. Severe pulmonary, renal or cardiac disease.

          5. Obese due to a clinically diagnosed endocrine disorder.

          6. Subjects with impaired liver function.

          7. History of peptic ulcer disease.

          8. History of malignant disease.

          9. Use of prescription, over the counter or herbal weight loss products.

         10. Pregnant or planning on pregnancy while enrolled in study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Noreen A Gannon</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic - MITG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aureo DePaula, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Especialidades</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Especialidades</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

